127 related articles for article (PubMed ID: 38091717)
1. Synthesis, molecular docking and biological evaluation of 1,2,4-oxadiazole based novel non-steroidal derivatives against prostate cancer.
Kumar S; Wadhwa P
Bioorg Chem; 2024 Feb; 143():107029. PubMed ID: 38091717
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
Bahashwan SA; Al-Omar MA; Ezzeldin E; Abdalla MM; Fayed AA; Amr AG
Chem Pharm Bull (Tokyo); 2011; 59(11):1363-8. PubMed ID: 22041072
[TBL] [Abstract][Full Text] [Related]
3. A Rationalized Approach to Design and Discover Novel Non-steroidal Derivatives through Computational Aid for the Treatment of Prostate Cancer.
Kumar S; Arora P; Wadhwa P; Kaur P
Curr Comput Aided Drug Des; 2024; 20(5):575-589. PubMed ID: 37365786
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
Kandil SB; Kariuki BM; McGuigan C; Westwell AD
Bioorg Med Chem Lett; 2021 Mar; 36():127817. PubMed ID: 33513386
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
8. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
9. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Pertusati F; Ferla S; Bassetto M; Brancale A; Khandil S; Westwell AD; McGuigan C
Eur J Med Chem; 2019 Oct; 180():1-14. PubMed ID: 31288149
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological characterization of a novel series of androgen receptor modulators.
Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
[TBL] [Abstract][Full Text] [Related]
12. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
15. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
[TBL] [Abstract][Full Text] [Related]
16. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]